Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Nitin Jain, Catherine Coombs, James D'Olimpio, Nirav Shah, Jacqueline Barrientos, Seung Tae Lee, Danielle Brander, John Nemunaitis, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Koji Yoshida, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2025) 146 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2025-3892

Published: 2025

Journal Articles

Baseline CD4 count is associated with early mortality in HIV-associated lymphoma: A retrospective cohort study

Emily Davidson, Olga Golubeva, Joseph Deng, Caroline Dunne, Jennie Law, Seung Tae Lee, Kathryn Kline

Blood (2025) 146 (Supplement 1): 3678.

https://doi.org/10.1182/blood-2025-3678

Published: 2025

Journal Articles

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Philippe Armand, Seung Tae Lee, Wojciech Jurczak, Don Stevens, Sylvain Choquet, Herve Ghesquieres, Lalita Norasetthada, Antonio Pinto, Güray Saydam, Heng Zhou, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 3745.

https://doi.org/10.1182/blood-2025-3745

Published: 2025

Journal Articles

Cell cycle-related genetic variants are frequently acquired at relapse of acute lymphoblastic leukemia and predict worse post-relapse prognosis

Jinho Lee, Namsoo Kim, Yu Jeong Choi, Seungmin Hahn, Wonkee AHN, Hye Won Kook, Hyunsoo Cho, Haerim Chung, Doh Yu Hwang, Jieun Jang, Seung-Tae Lee, Jong Rak Choi, June-won Cheong, Saeam Shin

Blood (2025) 146 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2025-3323

Published: 2025

Journal Articles

Varaser : Genetic individual identification free from direct raw data sharing

TAEK GYU LEE, Eunju Yeom, Yehyun Kang, Seoyoung Lim, Yu Jin Park, Jieun Jang, Seung-Tae Lee

Blood (2025) 146 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2025-6127

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Nitin Jain, Catherine C. Coombs, James D'Olimpio, Nirav N. Shah, Jacqueline C. Barrientos, Seung Tae Lee, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William G. Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2024-208549

Published: 2024

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda

Blood (2023) 142 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2023-182568

Published: 2023

Journal Articles

A Subset of Classical Hodgkin Lymphoma Cases Demonstrate CD19 Expression on Hodgkin Reed-Sternberg Cells By Immunohistochemistry

Sarah Helman, Fikru Merechi, Hanan Alharthy, Madhurima Koka, Michael Kallen, Aaron P. Rapoport, Jennie Law, Seung Tae Lee, Zeba N Singh

Blood (2023) 142 (Supplement 1): 6125.

https://doi.org/10.1182/blood-2023-174284

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2023-172537

Published: 2023

Journal Articles

HIV-Associated Lymphoma in an Urban Clinic Population: Epidemiology and Outcomes during the Antiretroviral Therapy Era

Kathryn Kline, Caroline Dunne, Jennie Law, Alonso Heredia, Anthony Devico, Mohammad Sajadi, Ben Atkinson, Seung Tae Lee

Blood (2023) 142 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2023-190032

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Sarit Assouline, Katharine L. Lewis, Rosemary Anne Harrup, Robert J Lutz, Jenny Thirlway, Jutta Deckert, David M Browning, Debra L Wood, Paul I. Nadler, Seung Tae Lee

Blood (2023) 142 (Supplement 1): 3095.

https://doi.org/10.1182/blood-2023-173955

Published: 2023

Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 434.

https://doi.org/10.1182/blood-2023-180173

Published: 2023

Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi

Blood (2023) 142 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2023-183002

Published: 2023

Journal Articles

Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Hanan Alharthy, Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Kathryn A.F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali

Blood (2022) 140 (Supplement 1): 9025–9026.

https://doi.org/10.1182/blood-2022-170688

Published: 2022

Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

Blood (2022) 140 (Supplement 1): 2289–2291.

https://doi.org/10.1182/blood-2022-167887

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Baseline CD4 count is associated with early mortality in HIV-associated lymphoma: A retrospective cohort study

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Cell cycle-related genetic variants are frequently acquired at relapse of acute lymphoblastic leukemia and predict worse post-relapse prognosis

Varaser : Genetic individual identification free from direct raw data sharing

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

A Subset of Classical Hodgkin Lymphoma Cases Demonstrate CD19 Expression on Hodgkin Reed-Sternberg Cells By Immunohistochemistry

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

HIV-Associated Lymphoma in an Urban Clinic Population: Epidemiology and Outcomes during the Antiretroviral Therapy Era

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only